Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Mercado Continuo Espanol  >  Grifols SA       ES0171996012

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials (€)
Sales 2016 4 144 M
EBIT 2016 1 027 M
Net income 2016 554 M
Debt 2016 3 514 M
Yield 2016 1,77%
Sales 2017 4 308 M
EBIT 2017 1 085 M
Net income 2017 631 M
Debt 2017 3 260 M
Yield 2017 1,94%
P/E ratio 2016 23,48
P/E ratio 2017 20,69
EV / Sales2016 3,71x
EV / Sales2017 3,51x
Capitalization 11 875 M
More Financials
Company
Grifols SA is a vertically integrated global producer of plasma derivatives.Its activities include sourcing raw material, manufacturing various plasma derivative products and selling and distributing final products to healthcare providers.The company operates through the following segments: ... 
Sector
Pharmaceuticals
Calendar
11/01Earnings Release
More about the company
Surperformance© ratings of Grifols SA
Trading Rating : Investor Rating :
More Ratings
Latest news on GRIFOLS SA
08/18 ARADIGM : Announces Second Quarter 2016 Financial Results
08/16 GRIFOLS : Grif_ls support the Canadian Blood Services' Missing Type Campaign
08/11 GRIFOLS : Doggett, delauro, murphy lead bipartisan push for zika testing of bloo..
08/01 GRIFOLS : The results of phase I clinical trial of the Araclon Biotech Alzheimer..
07/28 GRIFOLS : Award Winners of the 9th Annual Martin Villar Haemostasis Awards
07/28 GRIFOLS : Sales of the Bioscience Division grow by +7.0%, increasing Grifols' re..
07/27 GRIFOLS : Award Winners of the 9th Annual Martín Villar Haemostasis Awards
07/11 GRIFOLS : FDA Approves Use of Zika Virus Assay to Screen US Blood Supply
07/05 PEDIGRI® : the tool that increases the information transparency to the plasma-de..
07/01 HOLOGIC : FDA Approves Use of the Procleix Zika Virus Assay from Hologic and Gri..
More news
Sector news : Biopharmaceuticals
03:22p Stada shareholder AOC pushes through board reshuffle
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Biopharmaceuticals
News from SeekingAlpha
01/04 Midday Gainers / Losers
2015 Tracking John Paulson's Paulson & Company Portfolio - Q3 2015 Update
2015 TiGenix Achieves First Ever Success In Allogeneic Stem Cell Phase 3 Trial
2015 Tracking John Paulson's Paulson & Company Portfolio - Q2 2015 Update
2015 Tracking John Paulson's Paulson & Company Portfolio - Q1 2015 Update
Advertisement
Chart GRIFOLS SA
Duration : Period :
Grifols SA Technical Analysis Chart | ES0171996012 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 21,6 €
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Víctor Grifols Roura Chairman, President & Chief Executive Officer
Alfredo Arroyo Guerra Chief Financial Officer & Vice President
Eva Bastida Tubau VP, Director-Scientific & Medical Affairs
Vicente Blanquer Torre Vice President-Quality, Research & Development
Ramón Riera Roca Executive Director, VP-Marketing & Sales
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GRIFOLS SA0.00%13 294
CSL LIMITED3.89%37 907
ALEXION PHARMACEUTICAL..-32.04%29 069
GRIFOLS SA-10.20%13 294
BEIJING TIANTAN BIOLOG..11.05%3 041
JIANGXI BOYA BIO-PHARM..--.--%2 698
More Results